drugset / Trial / NCT02403362
Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis
Non-randomizedFactorialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety,efficacy， pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of EPO-018B in participants with chronic kidney disease (CKD) Who are not on dialysis
Timeline
- Start
- 2014-06
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegmolesatide | Peptide | 0.025 mg/kg | Subcutaneous |
| Subject | Pegmolesatide | Peptide | 0.05 mg/kg | Subcutaneous |
| Subject | Pegmolesatide | Peptide | 0.08 mg/kg | Subcutaneous |